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ABSTRACT: In the postgenome era, proteomics provides a powerful approach
for the analysis of normal and transformed cell functions, for the identification
of disease-specific targets, and for uncovering novel endpoints for the evalua-
tion of chemoprevention agents and drug toxicity. Unfortunately, the genomic
information that has greatly expounded the genetic basis of cancer does not
allow an accurate prediction of what is actually occurring at the protein level
within a given cell type at any given time. The gene expression program of a
given cell is affected by numerous factors in the in vivo environment resulting
from tissue complexity and organ system orchestration, with cells acting in
concert with each other and responding to changes in their microenvironment.
Repositories of genomic information can be considered master “inventory
lists” of genes and their maps, which need to be supplemented with protein-
derived information. The National Cancer Institute’s Early Detection Research
Network is employing proteomics, or “protein walking”, in the discovery and
evaluation of biomarkers for cancer detection and for the identification of
high-risk subjects. Armed with microdissection techniques, including the use
of Laser Capture Microdissection (LCM) to procure pure populations of cells
directly from human tissue, the Network is facilitating the development of tech-
nologies that can overcome the problem of tissue heterogeneity and address the
need to identify markers in easily accessible biological fluids. Proteomic
approaches complement plasma-based assays of circulating DNA for cancer
detection and risk assessment. LCM, coupled with downstream proteomics
applications, such as two-dimensional polyacrylamide gel electrophoresis and
SELDI (surface enhanced laser desorption ionization) separation followed by
mass spectrometry (MS) analysis, may greatly facilitate the characterization
and identification of protein expression changes that track normal and disease
phenotypes. We highlight recent work from Network investigators to demon-
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strate the potential of proteomics to identify proteins present in cancer tissues
and body fluids that are relevant for cancer screening.
KEYWORDS: Biomarkers; EDRN; LCM; MALDI; ProteinChip; Proteomics;
SELDI
INTRODUCTION
Genetic aberrations during carcinogenesis disturb the normal function of a cell,
primarily through their effect upon the proteins encoded in the altered/mutated
genome. Thus, while increasingly sophisticated techniques have rapidly expanded
our knowledge of events at the nucleic acid level, protein-based analyses and assays
remain desirable as they provide information that is more easily linked to function
than nucleic acid–based assays. From a practical point of view, assays of protein
tumor markers, due to their ease and robustness, lend themselves to routine clinical
practice. Screening, even for high-risk groups, could only be successful when the
procedures undertaken are simple, inexpensive, and minimally invasive. A most
effective approach is to develop protein-based tests for easily accessible biological
fluids such as urine, blood, feces, sputum, bladder, and bronchioalveolar lavage. The
development, in particular, of tests to evaluate secretory proteins has proven value in
the diagnosis of cancer and in the assessment of precancerous lesions. Proteomics
provides the means to achieve the goal of early cancer detection.
An important step in the new postgenome era is to decode the functions of the
huge numbers of new open reading frames (ORFs). Various avenues to elucidate
what unknown genes do and how they interact within an organism are being utilized,
including (1) the simultaneous assessment at the RNA level of all genes that are
expressed in a cell population or tissue and (2) the mapping and quantitation of all
the proteins expressed in a cell population or tissue.1,2 Valuable information that
cannot be accurately predicted from nucleic acid data, such as protein location and
posttranslational modification, may be obtained directly at the proteomic level. The
ensemble of proteomic information constitutes the body of knowledge of the
“proteome”, the total protein output encoded by a genome. Proteome research, or
proteomics, is an extension of protein (polypeptide) and gene-product mapping
(linking proteins to their encoding genes).3 The goal of proteomics is a comprehen-
sive, quantitative description of protein expression and of the changes associated
with biological perturbations such as disease (cancer) or drug treatment. Proteome
analysis can be undertaken independently of genomic or RNA analysis. Its ability to
identify and quantify proteins and confirm their expression and structure as
presumed from nucleic acid data is highly complementary to genomic science.
The human genome encodes for some 30,000 genes that are scattered among
3.2 billion nucleotides. Added complexity stems from the findings of alternative
splicing and due to the occurrence of posttranslational modifications that give rise to
several protein products from a given gene.2 The profiles of expressed proteins in
normal and cancer states are different as some genes are up- or downregulated,
whereas others are expressed constitutively.4 To generate these profiles, a variety of
technologies are employed for sample collection (cells, tissue, or fluid), processing
and analysis of samples, and storage of data. Cytosolic proteins are most readily
amenable to proteomic analysis. Whereas secreted proteins are easy to solubilize,
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their low abundance is problematic. On the other hand, membrane-bound proteins
both occur in low abundance and require additional steps for their solubilization
prior to analysis.5
TECHNOLOGIES INVOLVED
The most widely used techniques for the characterization of proteins are two-
dimensional gel electrophoresis (2-DGE), mass spectrometry (MS), amino acid
composition analysis, peptide sequence tagging, and high-throughput microchip
arrays. Matrix assisted laser desorption ionization (MALDI), surface enhanced laser
desorption ionization (SELDI), laser capture microdissection (LCM), and capillary
electrophoresis (CE) have been added to the proteomics tool set.6 We summarize
these technologies below.
Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) remains as the
standard high-resolution technique for protein separation and is the method of
choice when complex samples need to be characterized.7 Quantitative 2-D PAGE
can be used for protein-based gene expression analysis and allows large-scale
screening of the protein component of normal or cancer cells or tissues. The separa-
tion range of 2-D gels can extend from the most acidic to the most basic proteins as
needed for specific applications.
MS has been used for protein identification and sequencing and has given a major
impetus to proteomics.8–10 For sequence-based determinations by MS, proteins are
cleaved with trypsin or cyanogen bromide into peptide fragments and separated by
high-pressure liquid chromatography (HPLC) followed by tandem mass spectrome-
try. For protein identification, the mass spectra of peptides from digested proteins are
utilized to search sequence databases. Modified peptides, such as those containing
an oxidized methionine, can be identified by accounting for modifications. If the
peptide under investigation can be matched correctly to the mass value predicted by
genomic sequencing, it can be deemed unmodified. However, if a particular peptide
does not have a match in the sequence of a particular candidate protein, specific
modifications can be inferred that may account for mass discrepancy. The confi-
dence achieved in matches obtained from peptide-mass fingerprinting can be signif-
icantly increased by additional sequence information from within the proteolytically
derived peptide fragments. This approach is termed “peptide sequence tagging”. The
short (2–4 amino acids) sequence can be derived by fragmentation of the parent ion
into three complementary segments: the mass of an N-terminal fragment, the mass
of a C-terminal fragment, and the partial amino acid sequence between them.
Amino acid composition analysis is an efficient method for protein identifica-
tion.11 The method is complementary to MS and represents a useful analytical tool
for the mapping of proteins of interest.
The handling of protein samples to be separated by 2-D PAGE is still very much
a manual process. High-throughput screening (HTS) in proteome analysis needs
improvement through automation.12 Although the current methodologies to process
samples for proteome analysis are feasible, a manual approach is incompatible with
the industrial scale needed to conduct genomic style analyses. Studies such as those
of Aicher et al.,13 who identified an association between decreased calcium-binding
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protein, calbindin-D 28-kDa, urinary calcium wasting, and intratubular cortico-
medullary calcification in rat kidney using proteomics, can be substantially facilitated
through automation.
MS-based methodologies span the vast expanse of proteomics and drug discovery.
Both electrospray ionization (ESI) and MALDI support proteomics-based research
projects by identifying proteins separated and isolated by PAGE. MALDI/MS-based
surface scanning of one-dimensional isoelectric focusing gels, “virtual 2-D gel
electrophoresis”, represents a potentially high-throughput means to map proteins
and to determine protein profiles. MS can also be used to directly study the covalent
and noncovalent interactions of drug molecules and biomolecular targets.
Capillary electrophoresis/time-of-flight mass spectrometry (CE/TOFMS) has
been used for analysis of in-gel digests of protein spots excised from 2-D PAGE gels.
An off-line purification and preconcentration procedure with a Zip Tip is used before
CE/TOFMS analysis, which allows for detection of protein spots with <1 picomole
of material from 2-D gels. The off-line procedure provides sufficient purification for
analysis while maintaining the quality of the CE separation. Using this procedure,
proteins from Coomassie Blue and zinc negatively stained gels can be identified by
database searching based on the peptide maps generated. CE/TOF tandem mass
spectrometry is used to confirm database query results and to provide structural
analysis of peptides that do not match the expected peptide maps derived from the
database search in order to identify structural modifications.
Affinity mass spectrometry offers a novel proteomic approach for the identifica-
tion and measurement of cancer-associated biomarkers. Based on the work of
Hutchens and Yip,14 Ciphergen Biosystems (Fremont, CA) has developed the
SELDI ProteinChip MS technology that brings to the field of proteomics a user-
friendly methodology.15,16 SELDI has several advantages over other existing
technologies, such as liquid chromatography–mass spectrometry (LC-MS), 2-D gel
electrophoresis–coupled MS (2DGE-MS), ELISA, and fluorescent-based binding
assays for high-throughput screening, due to its versatility, ease of use, speed, and
cost. It is rapid, reproducible, and highly sensitive (i.e., detection limit in the femto-
molar range) and is readily adaptable to a diagnostic format.10 Its major limitations
are the difficulty in identifying proteins detected in mass spectra and the limited
ability to detect most proteins in complex samples.17
The most tedious job in proteomics is sample preparation, as some proteins are
insoluble in a heterogeneous mixture of cells.5 An important advance in sample
preparation is the development of LCM.18 Prior to LCM, obtaining “pure” cell
populations from tissues was performed manually. Although manual microdissection
can achieve good precision, it is time-consuming and labor-intensive, and requires a
high degree of manual dexterity. The LCM system yields a one-step procurement of
selected human cell populations from a section of complex, heterogeneous tissue.
LCM has been successfully used to obtain pure populations of cancer cells from both
frozen and paraffin-embedded tissues, stained or unstained, for molecular analysis
of macromolecules. LCM is capable of isolating single cells, making it possible to
procure pure populations of neoplastic cells from lesions less than 1 mm in diameter
without encroachment of adjacent nonneoplastic cells. Using this technique,
matched normal epithelium, stroma, benign, preneoplastic neoplasia, and cancer
cells from the same specimen have been successfully isolated.
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PROTEOMICS APPROACHES IN THE EARLY DETECTION
RESEARCH NETWORK (EDRN)
General strategies commonly used to detect and analyze cancer-associated
proteins by 2-DGE and SELDI are shown in FIGURE 1. EDRN investigators have
applied proteomic approaches to identify and characterize potential markers for the
early detection of cancer from samples such as serum, nipple aspirate, urine, seminal
FIGURE 1. General strategies for detection and characterization of cancer-associated
proteins.
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plasma, and microdissected cells. At the University of Michigan, the focus of the
research is on the detection and identification of protein antigens that induce humoral
response and on proteins secreted by tumor cells in lung and colon cancer. Tumor
proteins may induce a humoral response as a result of their overexpression,
increased turnover, posttranslational modification, or other unique processing in
neoplastic cells. There is evidence that a humoral response to such protein antigens
may predate the diagnosis of cancer, indicating the utility of assays for specific
tumor protein antigens or antibodies in serum or biological fluids for the early de-
tection of cancer. A large number of proteins of interest have been characterized and
their derived information has been entered into a queryable database. Several lung
cancer–specific protein markers have been identified and are being characterized
(FIG. 2).
The focus of the Eastern Virginia Medical School (EVMS) Biomarker Develop-
mental Laboratory is the application of the SELDI ProteinChip–Surface MS sys-
tem to the discovery of cancer-associated biomarkers, with a major emphasis on
prostate cancer (PCA). A previous report from this laboratory described SELDI
methodologies for detecting known prostate cancer biomarkers, such as prostate
specific antigen (PSA), prostate acid phosphatase (PAP), and prostate specific mem-
FIGURE 2. A 2-D PAGE master image showing a subset of proteins identified in lung
tumors.
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brane antigen (PSMA) in cell lysates from LCM microdissected cells and body
fluids (i.e., seminal plasma and serum).19
Ongoing studies are directed at biomarker discovery and assay development. For
the discovery phase, efforts have focused on SELDI analyses of cell lysates from
microdissected prostate cells and seminal plasma. Pure populations of cells, that is,
cancer, benign, and normal epithelium, were obtained from the same patients’ sur-
gical tissue specimens using the Pixcell-II–Laser Capture Microdissection micro-
scope (Arcturus Engineering, Mountain View, CA). Approximately 2000–3000 cells
were procured for each cell type, cell lysates were prepared, and the lysates were
subjected to SELDI analysis. Three proteins (33 kDa, 8.5 kDa, and 9.5 kDa) were
found to be overexpressed in PCA cells compared to benign and normal epithelial
cells. An interesting finding was the observation that, when the 33-kDa protein was
overexpressed, the free form of PSA appeared to be underexpressed. Using a ratio of
peak intensity of the 33-kDa with the 28-kDa free PSA protein, the cancer popula-
tion could be clearly differentiated from the benign and normal cell populations
(p < 0.002). Overall, PSA appears to be downregulated in cancer compared to normal
epithelium in the same tissue specimen, confirming a recent report.20 Perhaps most
notable has been the recent discovery of four proteins under 10 kDa that are over-
expressed in preneoplastic lesions, that is, prostate intraepithelial neoplasia (PIN),
and that continue to be upregulated in cancer. Efforts are in progress to validate
whether these proteins represent an early protein signature of neoplasia, to isolate
and identify these potential diagnostic biomarkers, and to determine if they are also
present in body fluids. Other reports coupling LCM with SELDI describe similar
findings with the generation of distinct protein profiles for each cancer type
evaluated.21
An application of SELDI is the simultaneous analysis of multiple proteins to
establish “fingerprint” profiles that discriminate cancer from noncancer. The
premise for this approach is that no single protein by itself will improve the early
detection/diagnosis of cancer. Seminal plasma and serum from normal age-matched
men and from patients diagnosed with benign prostate hyperplasia (BPH) or PCA
were subjected to SELDI protein profiling. A representative example of SELDI
analysis of serum is shown in FIGURE 3. The raw time-of-flight data were analyzed
by two different learning algorithms developed by investigators at the EDRN Data
Management Coordinating Center (i.e., Binary Combinations and Wavelet algo-
rithms). For seminal plasma, using the Binary Combinations algorithm, a sensitivity
of 88% and a specificity of 89% were obtained. This protein profiling algorithm,
which analyzes combinations of 8 proteins, correctly “diagnosed” 21/24 cancers
(88%), 21/23 BPH (91%), and 25/28 normals (89%). For serum, 167 sera from PCA
patients and 96 sera from normal age-matched men were used to train the Wavelet
algorithm. The analyses of 11 protein masses resulted in a specificity of 100% and
a sensitivity of 97% for the training set. A test set of samples consisting of 30 nor-
mals and 15 cancers, all coded, yielded correct diagnosis for all 30 normals (100%)
and 14/15 cancers (93%). A SELDI protein profiling study of urine from bladder
cancer patients resulted in an improved detection rate of low-grade bladder cancer
by 44% (to 77%) compared to voided urine or bladder washing cytology (33%). Five
proteins and 7 protein clusters between 2000 and 20,000 daltons were used in this
analysis. One of the proteins (3.3 kDa) was identified as defensin.22 These prelimi-
nary studies are very encouraging and demonstrate that SELDI fingerprint protein
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profiling coupled with a learning algorithm may lead to innovative clinical assay for
the early detection/diagnosis of prostate and bladder cancers. With the SELDI
approach, protein identification may not be necessary for development of clinical
assays based on the SELDI protein profile.
Besides discovery and protein profiling applications, SELDI can also be used in
an immunoassay platform. For this application, antibody rather than a chemical
matrix is bound to the chip array to capture the protein (antigen). The EVMS lab has
successfully used the SELDI immunoassay to measure PSA and PSMA in body
fluids, in both single and multiplex formats.19,23 Using the SELDI/PSMA immuno-
assay, it was possible to discriminate PCA patients from patients with BPH and nor-
mal age-matched men (p < 0.001). Importantly, all patients with serum PSA values
between 4 and 10 ng/mL were correctly identified as either BPH or PCA. This is a
significant observation since the specificity of PSA in the 4–10 ng/mL range is only
25–30%. If validated, PSMA may be a clinically useful biomarker to improve the
accuracy for differential diagnosis of BPH and PCA. The SELDI ProteinChip sys-
tem, as shown in these studies, is a powerful and innovative proteomic technology
for biomarker discovery and diagnostic/prognostic assay development. A major
advantage of SELDI over other proteomic technologies is its versatility. Not only can
SELDI be used for biomarker discovery, but the same platform can be utilized to
FIGURE 3. Representative SELDI retentate map of serum from a patient diagnosed with
prostate cancer (C), compared to the retentate maps of sera from a patient with benign prostate
hyperplasia (B) and a normal age-matched male donor (N). The raw mass spectra are shown in
the top three panels; gel views are shown on the bottom. Only the low mass region (2–10 kDa)
of the protein profiles is shown. The asterisks (*) identify those proteins underexpressed, and the
arrows identify those proteins overexpressed in the prostate cancer specimen.
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develop clinical assays, such as protein profiling and immunoassays for simulta-
neous analyses of multiple biomarkers. The promising results obtained with prostate
and bladder cancer suggest that SELDI will be applicable to all human solid cancers.
Research by EDRN investigators at the Georgetown University Lombardi Cancer
Center aims to characterize differences in protein signatures between foci of normal
breast epithelium, ductal carcinoma in situ (DCIS), and invasive cancer from fresh
surgical specimens; to determine whether differences identified above can be
detected in nipple aspirate fluid (NAF) samples from women without breast abnor-
malities, with DCIS, or with early invasive breast cancer; and to determine whether
differentially expressed proteins can be detected in serum samples from women with
different stages of breast cancer development. A number of potential candidates have
been identified using LCM- and SELDI-based approaches.
Like the EVMS team, investigators at the M. D. Anderson Cancer Center have
also discovered differentially expressed proteins in urine from patients with bladder
cancer using SELDI. Most of these proteins are of low molecular mass. Analysis of
the urine from patients with bladder squamous cell carcinoma (SSC) has found a
number of significant differentiation markers, such as the presence of keratins 10,
13, 15, and 19, and loss of a number of proteins, including glutathione-S-transferase.
Another putative urinary SCC marker, psoriasin, a calcium-binding protein that is
widely expressed in tissues containing stratified squamous epithelium, has also been
studied.
Thus, a number of potential biomarkers have been identified by EDRN investiga-
tors, which will be validated in different laboratories using a large number of sam-
ples. If validated, these markers would be extremely valuable for screening
populations at high risk for cancer and perhaps developing prevention strategies for
a variety of cancers.
GENOMIC AND PROTEOMIC APPROACHES ARE COMPLEMENTARY
Studying individual proteins in the context of other cellular proteins is comple-
mentary to the information gathered from a genomic-based approach. The human
genome sequence provides a framework for proteomics.2 Proteome analysis already
represents a means of efficiently complementing differential display (DD), high-
density expression arrays (HDEA), expressed sequence tags (ESTs), direct or
suppressive subtraction hybridization (SSH), chromosomal linkage studies, and
nucleic acid sequencing as a problem-solving tool in molecular biology. DNA
sequence information alone cannot predict the efficiency of translation of gene
products, their relative concentrations, the extent of posttranslational modifications,
and the biological consequences of altered gene expression.
Proteomics complements, but certainly does not replace, other technologies
employed in the study of molecular processes within cells. Cellular and molecular
biology dictate that information pertaining to DNA and RNA must be supplemented
by corresponding information at the level of protein translation. Currently, the
throughput of proteomic analysis is lagging behind that using other approaches
based on nucleic acids. However, proteomics is still in its early phase of development
and the field is poised for major expansion. The mapping of various proteomes
including identification of posttranslational modifications such as phosphorylation
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promises to provide a very powerful means for investigating a wide variety of sig-
naling phenomena, including cross talk between different signaling pathways, acti-
vation or inactivation of particular pathways by endogenous or exogenous cofactors,
and even uncovering consequences of genetic defects in signaling cascades.
One limitation of proteome studies is its inability to efficiently resolve low-
abundance proteins on 2-D gels. The sensitivity of the staining techniques will allow
only those proteins present at more than 0.1 ng to be visualized (by silver staining).
Furthermore, electrotransfer to PVDF or nitrocellulose membrane as well as the
extensive staining/destaining/washing procedures involved contribute to a signifi-
cant amount of protein loss before any molecular characterization can be attempted.
Since peptide-mass fingerprinting and protein sequencing via MS are capable of
characterizing protein at the femtomole level, the limiting factor is the visualization
of proteins on 2-D gels and transfer membranes. However, the advancement made
by Ciphergen Biosystems employing SELDI has improved visualizing of proteins
significantly in the range of 2–10 kDa.
Proteome analysis has additional limitations. Proteome analysis is unlikely to
detect point mutations or minor insertions, deletions, or recombination events. There
is, however, at least one example where a point mutation in lactate dehydrogenase
(LDH) was detected. The mutated version of LDH had reduced substrate binding
specificity.24 Proteome analysis is also not able to detect all possible gene products
associated with every gene/ORF within a genome due to the phenomenon of tempo-
rarily restricted gene expression as all genes are not expressed constitutively. This
restriction is linked to suppression (or induction) of gene activity associated with a
variety of stimuli occurring as a result of disease state, environmental changes,
stress, embryological development, or housekeeping activities. The influence of the
relationship between the length of the cell cycle or replication time and the half-life
of both protein and mRNA gene products is critical to the relative abundance of
intracellular proteins.
The principal technical challenge in proteomics is achieving a level of compre-
hensiveness that matches that of genomics, that is, complete coverage. This is clearly
a much harder task with proteins than with nucleic acids. In the first place, genes are
approximately equimolar in genomic DNA, whereas proteins may span seven or
eight orders of magnitude in functional abundance in a cell type such as the hepato-
cyte and potentially wider ranges in distributed media such as serum. Very few
detection methods exist that are usable over seven orders of magnitude and, if one
could be found, problems remain such as that of abundant spots obscuring minor
ones in 2-D gels. The relative chemical homogeneity of DNA and the availability of
technologies and resources such as reverse transcriptases, restriction enzymes, PCR,
and sequence complementarity have all contributed to the ease of genomics as com-
pared to proteomics. There may be a temptation to assert that complete proteomes
are just around the corner, an assertion that represents a major leap of technological
faith at this point.
BIOINFORMATICS AND PROTEOMICS
Like the genome project, more sophisticated data mining and learning algorithm
software programs will be required to reproducibly and efficiently collect and ana-
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lyze the tens of thousands of bits of information being generated by the proteomic
technologies. Furthermore, current proteomic projects are generating a wealth of
data for a wide range of tissues, and it is critical for the success of any study that the
results produced are organized and presented in a form that makes analysis as simple
and accessible as possible. To this end, a number of databases have been constructed
(TABLE 1, FIG. 2), containing both visual and textual data with extensive links to both
protein and nucleic acid databases. The ability to effectively search such databases
for the identification of protein spots from 2-DGE has become an essential step in
the study of proteomes. The ability of analytical techniques used in protein char-
acterization and their associated database query programs to determine identity at
the functional group level has been examined for proteins with low levels of
homology at the gene/protein sequence level. Such theoretical data manipulations
may provide the means to predict the utility of data acquired experimentally with
nonsequence-dependent software for proteome analysis. Eight organisms have now
been fully sequenced and distributed within publicly accessible gene and protein
databases. These databases of model organisms have been proposed as a starting
point for studies of either the total proteome or the “functional” proteome (defined
as gene-product expression under specific environmental or laboratory conditions).
The proteome of the yeast, Saccharomyces cerevisiae, has been studied extensively
by 2-D PAGE of cells grown under a variety of conditions. Approximately 600 vis-
ible protein spots have been characterized from whole-cell extract. These protein
spots have been identified by amino acid analysis, peptide mass fingerprinting, and
associated sequence tags in conjunction with nanoelectrospray tandem mass
spectrometry and conventional N-terminal microsequencing.
TABLE 1. Protein databases on the Internet
Web address Description
http://expasy.hcuge.ch Access to several protein databases using 
ExPASy server




To align protein fingerprints
http://www.ncbi.nlm.nih.gov/BLAST To search for homologues
http://www.pdb.bln.gov PDB home-page (3-D structures)
http://www.ncbi.nlm.nih.gov/Structure/
cn3d.html
To view structure in 3-D (ASN.1 format)
ftp://ftp.pdb.bnl.gov/pub/kinemage To view structures published in Protein 
Science and other journals
ftp://ftp.pdb.bnl.gov/pub/other-software/
Rasmol
To download by anonymous ftp Rasmol
http://www.prosci.uci.edu/scop To compare structures
http://www.embl-heidelberg.de/Service To see secondary structure
http://motif.stanford.edu/emotif To align proteins
http://biobase.dk/cgi-bin/celis To search disease-related proteome database
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CONCLUSIONS
The inside of a cell is a crowded and dynamic compartment, where proteins are
perpetually being produced and degraded. Understanding the structures, interactions,
and functions of all of a cell’s proteins is one of the grand goals of the postgenome
era. Prospects for introducing proteomics technologies into the clinical laboratory
will depend on their robustness, their user-friendliness, and the clinical relevance of
the added information they provide that cannot be captured through other
technologies in use in the clinical laboratory. The primary focus of proteome
analysis is the rapid characterization of gene products as either “previously studied”
or “novel”. The overall goal is to apply this information for cancer screening and risk
assessment. Efforts made in the EDRN are directed towards identification and
characterization of biomarkers that can be used for early cancer detection and risk
assessment.
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